Symbols / ORKA Stock $61.93 -3.08% Oruka Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
ORKA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Lawrence Otto Klein Ph.D.
Exch · Country NGM · United States
Market Cap 3.74B
Enterprise Value 3.35B
Income -94.19M
Sales —
FCF (ttm) -56.13M
Book/sh 9.63
Cash/sh 6.45
Employees 68
Insider 10d —
IPO Aug 08, 1997
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -24.70
PEG —
P/S —
P/B 6.43
P/C —
EV/EBITDA -25.14
EV/Sales —
Quick Ratio 23.38
Current Ratio 23.76
Debt/Eq 0.37
LT Debt/Eq —
EPS (ttm) -1.93
EPS next Y -2.51
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-13
ROA -18.92%
ROE -27.31%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 60.31M
Shs Float 50.93M
Insider Own 1.36%
Instit Own 92.05%
Short Float 17.87%
Short Ratio 3.48
Short Interest 6.99M
52W High 91.00
vs 52W High -31.95%
52W Low 9.40
vs 52W Low 558.83%
Beta —
Impl. Vol. 70.78%
Rel Volume 1.06
Avg Volume 1.31M
Volume 1.39M
Target (mean) $142.17
Tgt Median $141.50
Tgt Low $100.00
Tgt High $200.00
# Analysts 12
Recom Strong_buy
Prev Close $63.90
Price $61.93
Change -3.08%
About

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$142.17
Mean price target
2. Current target
$61.93
Latest analyst target
3. DCF / Fair value
$-16.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$61.93
Low
$100.00
High
$200.00
Mean
$142.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-14 reit BTIG Buy → Buy $151
2026-04-29 main HC Wainwright & Co. Buy → Buy $120
2026-04-28 main UBS Buy → Buy $100
2026-04-28 main Barclays Overweight → Overweight $160
2026-04-27 main BTIG Buy → Buy $151
2026-04-15 main Wedbush Outperform → Outperform $85
2026-04-13 reit Guggenheim Buy → Buy $125
2026-04-13 main BTIG Buy → Buy $78
2026-04-13 main HC Wainwright & Co. Buy → Buy $70
2026-04-09 reit Guggenheim Buy → Buy $125
2026-04-07 main Barclays Overweight → Overweight $78
2026-04-06 main UBS Buy → Buy $75
2026-04-06 main Guggenheim Buy → Buy $125
2026-03-16 main Leerink Partners Outperform → Outperform $86
2026-03-13 main Barclays Overweight → Overweight $50
2026-03-13 reit BTIG Buy → Buy $73
2026-03-13 main Stifel Buy → Buy $72
2026-03-13 reit Guggenheim Buy → Buy $60
2026-03-13 reit Wedbush Outperform → Outperform $45
2026-01-13 main Wedbush Outperform → Outperform $45
News
RSS: Latest ORKA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-01 SANDLER LAURA LEE Chief Operating Officer — 5,000 $62.58 $319,384
2026-05-01 SANDLER LAURA LEE Chief Operating Officer — 5,000 $7.80 $39,000
2026-04-15 GONCALVES JOANA Officer — 7,000 $65.73 $462,830
2026-04-15 GONCALVES JOANA Officer — 7,000 $6.84 $51,240
2026-03-16 QUINLAN PAUL T General Counsel — 733 $41.30 $30,273
2026-03-16 GONCALVES JOANA Officer — 7,641 $40.11 $312,560
2026-03-16 KLEIN LAWRENCE OTTO Chief Executive Officer — 1,729 $41.30 $71,408
2026-03-16 AGARWAL ARJUN Officer — 395 $41.30 $16,314
2026-03-16 SANDLER LAURA LEE Chief Operating Officer — 600 $41.30 $24,780
2026-03-16 GONCALVES JOANA Officer — 7,000 $6.84 $51,240
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31
Total Revenue
0.00
Operating Revenue
0.00
Operating Expense
122.05
Research And Development
100.64
Selling General And Administration
21.41
General And Administrative Expense
21.41
Salaries And Wages
15.03
Other Gand A
6.38
Total Expenses
122.05
Operating Income
-122.05
Total Operating Income As Reported
-122.05
EBITDA
-105.35
Normalized EBITDA
-105.35
Reconciled Depreciation
0.08
EBIT
-105.43
Net Income
-105.43
Pretax Income
-105.43
Net Non Operating Interest Income Expense
16.63
Interest Expense Non Operating
0.00
Net Interest Income
16.63
Interest Expense
0.00
Interest Income Non Operating
16.63
Interest Income
16.63
Other Income Expense
-0.01
Other Non Operating Income Expenses
-0.01
Tax Rate For Calcs
0.00
Tax Effect Of Unusual Items
0.00
Net Income Including Noncontrolling Interests
-105.43
Net Income From Continuing Operation Net Minority Interest
-105.43
Net Income From Continuing And Discontinued Operation
-105.43
Net Income Continuous Operations
-105.43
Normalized Income
-105.43
Net Income Common Stockholders
-105.43
Diluted NI Availto Com Stockholders
-105.43
Line Item Trend 2025-12-31 2024-12-31
Total Assets
488.62
+23.38%
396.02
Current Assets
343.86
-8.76%
376.87
Cash Cash Equivalents And Short Term Investments
337.04
-10.28%
375.65
Cash And Cash Equivalents
46.94
-23.78%
61.58
Other Short Term Investments
290.11
-7.63%
314.07
Receivables
—
0.00
Other Current Assets
6.81
+457.99%
1.22
Total Non Current Assets
144.76
+655.93%
19.15
Net PPE
2.12
+104.05%
1.04
Gross PPE
2.12
+104.05%
1.04
Other Properties
2.12
+104.05%
1.04
Investments And Advances
142.54
+688.86%
18.07
Other Non Current Assets
0.10
+139.53%
0.04
Total Liabilities Net Minority Interest
19.62
+17.27%
16.73
Current Liabilities
15.37
+17.87%
13.04
Payables And Accrued Expenses
9.49
-12.05%
10.79
Payables
4.16
-56.09%
9.48
Accounts Payable
4.16
+20.02%
3.46
Current Accrued Expenses
5.33
+308.05%
1.30
Pensionand Other Post Retirement Benefit Plans Current
5.27
+158.01%
2.04
Current Debt And Capital Lease Obligation
0.62
+190.61%
0.21
Current Capital Lease Obligation
0.62
+190.61%
0.21
Total Non Current Liabilities Net Minority Interest
4.24
+15.14%
3.69
Long Term Debt And Capital Lease Obligation
1.31
+73.91%
0.76
Long Term Capital Lease Obligation
1.31
+73.91%
0.76
Preferred Securities Outside Stock Equity
2.93
+0.00%
2.93
Stockholders Equity
469.00
+23.65%
379.29
Common Stock Equity
469.00
+23.65%
379.29
Capital Stock
0.05
+32.43%
0.04
Common Stock
0.05
+32.43%
0.04
Preferred Stock
—
2.93
Share Issued
48.72
+30.13%
37.44
Ordinary Shares Number
48.72
+30.13%
37.44
Additional Paid In Capital
657.56
+42.02%
463.02
Retained Earnings
-189.16
-125.93%
-83.72
Gains Losses Not Affecting Retained Earnings
0.55
+1431.71%
-0.04
Other Equity Adjustments
0.55
+1431.71%
-0.04
Total Equity Gross Minority Interest
469.00
+23.65%
379.29
Total Capitalization
469.00
+23.65%
379.29
Working Capital
328.48
-9.71%
363.83
Invested Capital
469.00
+23.65%
379.29
Total Debt
1.93
+99.59%
0.97
Capital Lease Obligations
1.93
+99.59%
0.97
Net Tangible Assets
469.00
+23.65%
379.29
Tangible Book Value
469.00
+23.65%
379.29
Available For Sale Securities
142.54
+688.86%
18.07
Dueto Related Parties Current
0.01
-99.85%
6.02
Investmentin Financial Assets
142.54
+688.86%
18.07
Preferred Stock Equity
—
2.93
Line Item Trend 2025-12-31
Operating Cash Flow
-88.21
Cash Flow From Continuing Operating Activities
-88.21
Net Income From Continuing Operations
-105.43
Depreciation Amortization Depletion
0.08
Depreciation
0.08
Depreciation And Amortization
0.08
Other Non Cash Items
-4.54
Stock Based Compensation
24.24
Change In Working Capital
-2.56
Change In Prepaid Assets
-3.97
Change In Payables And Accrued Expense
1.93
Change In Accrued Expense
7.25
Change In Payable
-5.32
Change In Account Payable
-5.32
Change In Other Current Assets
-0.06
Change In Other Current Liabilities
-0.45
Investing Cash Flow
-96.75
Cash Flow From Continuing Investing Activities
-96.75
Net PPE Purchase And Sale
-0.21
Purchase Of PPE
-0.21
Capital Expenditure
-0.21
Net Investment Purchase And Sale
-96.54
Purchase Of Investment
-520.96
Sale Of Investment
424.42
Financing Cash Flow
170.31
Cash Flow From Continuing Financing Activities
170.31
Net Issuance Payments Of Debt
0.00
Issuance Of Debt
0.00
Long Term Debt Issuance
0.00
Net Long Term Debt Issuance
0.00
Net Common Stock Issuance
0.67
Net Other Financing Charges
169.64
Changes In Cash
-14.64
Beginning Cash Position
61.58
End Cash Position
46.94
Free Cash Flow
-88.42
Common Stock Issuance
0.67
Issuance Of Capital Stock
0.67
Net Preferred Stock Issuance
0.00
Preferred Stock Issuance
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category